Sign In
Last checked at 
20 Oct 2025 10:17
Board Change
· Robert Ghenchev, Non-Executive Director, has stepped down from the Board following his departure from Novo Holdings US
Oxford, UK - 20 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Robert Ghenchev, Non-Executive Director, has stepped down from the OXB Board with immediate effect, following his departure from Novo Holdings US to pursue other opportunities.
Robert Ghenchev, outgoing Non-Executive Director of OXB, stated: "It has been a pleasure to serve on the Board of OXB, during which time the Company has made strong progress in executing its strategy and strengthening its position as a leading global pure-play cell and gene therapy CDMO. I have great confidence in the Company's leadership and wish the Board and wider team every success for the future."
Dr. Roch Doliveux, Chair of OXB, commented: "On behalf of the Board, I would like to take this opportunity to thank Rob for his excellent contributions to the Board over the past six years, a period of significant transformation for OXB, and wish him the very best for his future."
Novo Holdings A/S, a major shareholder in OXB, has reserved the right to nominate another person to be a shareholder Director, subject to the approval of OXB's Board of Directors. OXB will provide any further update to the market in due course, as appropriate.
-Ends-
Enquiries:
OXB:
T: +44 (0) 1865 509 737 / E: ir@oxb.com
Sophia Bolhassan, Head of Investor Relations
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Follow the stocks
